These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26810596)

  • 1. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Bui AH; Cannon CP; Steg PG; Storey RF; Husted S; Guo J; Im K; James SK; Michelson EL; Himmelmann A; Held C; Varenhorst C; Wallentin L; Scirica BM
    Circ Arrhythm Electrophysiol; 2016 Feb; 9(2):e002951. PubMed ID: 26810596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
    Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
    Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
    Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Andell P; James SK; Cannon CP; Cyr DD; Himmelmann A; Husted S; Keltai M; Koul S; Santoso A; Steg PG; Storey RF; Wallentin L; Erlinge D;
    J Am Heart Assoc; 2015 Oct; 4(10):e002490. PubMed ID: 26452988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
    Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
    Armstrong PW; Siha H; Fu Y; Westerhout CM; Steg PG; James SK; Storey RF; Horrow J; Katus H; Clemmensen P; Harrington RA; Wallentin L
    Circulation; 2012 Jan; 125(3):514-21. PubMed ID: 22179530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
    Akerblom Å; Wallentin L; Siegbahn A; Becker RC; Budaj A; Buck K; Giannitsis E; Horrow J; Husted S; Katus HA; Steg PG; Storey RF; Åsenblad N; James SK
    Clin Chem; 2012 Jan; 58(1):190-9. PubMed ID: 22126936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
    Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
    JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
    G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
    Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L;
    Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
    Lindholm D; Hagström E; James SK; Becker RC; Cannon CP; Himmelmann A; Katus HA; Maurer G; López-Sendón JL; Steg PG; Storey RF; Siegbahn A; Wallentin L
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
    Akerblom A; Wallentin L; Siegbahn A; Becker RC; Budaj A; Horrow J; Husted S; Katus H; Claeys MJ; Storey RF; Asenblad N; James SK
    Am Heart J; 2012 Nov; 164(5):728-34. PubMed ID: 23137503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
    Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
    Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
    Varenhorst C; Alström U; Braun OÖ; Storey RF; Mahaffey KW; Bertilsson M; Cannon CP; Scirica BM; Himmelmann A; James SK; Wallentin L; Held C
    Heart; 2014 Nov; 100(22):1762-9. PubMed ID: 24957530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
    Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Lim ST; Cannon CP; Katus HA; Wallentin L
    Am J Cardiol; 2011 Dec; 108(11):1542-6. PubMed ID: 21890085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
    Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
    J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
    Cowper PA; Pan W; Anstrom KJ; Kaul P; Wallentin L; Davidson-Ray L; Nikolic E; Janzon M; Levin LÅ; Cannon CP; Harrington RA; Mark DB
    J Am Coll Cardiol; 2015 Feb; 65(5):465-76. PubMed ID: 25660925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
    Ueland T; Åkerblom A; Ghukasyan T; Michelsen AE; Aukrust P; Becker RC; Bertilsson M; Himmelmann A; James SK; Siegbahn A; Storey RF; Kontny F; Wallentin L;
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29330256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.